Robert J Pelham

US Patent:

20120046186, Feb 23, 2012

Filed:

Aug 16, 2011

Appl. No.:

13/211148

Inventors:

ROBERT J. PELHAM - BELMONT CA, US
KELLY A. HARRADINE - PACIFICA CA, US
JOFFRE B. BAKER - MONTARA CA, US

International Classification:

C40B 30/04
G01N 33/566
G01N 33/577
C12Q 1/68

US Classification:

506 9, 435 611, 435 71, 435 79

Abstract:

The present invention provides methods for predicting a likelihood that a patient with cancer will exhibit a positive response to a treatment with a platinum-based chemotherapy drug. The methods generally involve determining an expression level of a gene product that correlates with responsiveness to treatment with a platinum-based chemotherapy drug. In an embodiment of the invention, the platinum-based chemotherapy drug is oxaliplatin, and the cancer is colorectal cancer.

US Patent:

20130196321, Aug 1, 2013

Filed:

Jan 28, 2013

Appl. No.:

13/752199

Inventors:

Mark Lee - Los Altos Hills CA, US
William Novotny - Menlo Park CA, US
Tara Maddala - Sunnyvale CA, US
Michael Crager - Menlo Park CA, US
Diana Cherbavaz - San Francisco CA, US
Robert J. Pelham - Belmont CA, US
Carl L. Millward - Burlingame CA, US
Dejan Knezevic - Palo Alto CA, US

Assignee:

GENOMIC HEALTH, INC. - Redwood City CA

International Classification:

G06F 19/20
C12Q 1/68

US Classification:

435 611, 435 612, 702 19

Abstract:

The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.

US Patent:

20130274127, Oct 17, 2013

Filed:

Mar 14, 2013

Appl. No.:

13/804351

Inventors:

Robert J. Pelham - Belmont CA, US
Kevin A. Kwei - Mountain View CA, US

Assignee:

GENOMIC HEALTH, INC. - Redwood City CA

International Classification:

C12Q 1/68

US Classification:

506 9, 435 612, 435375, 435 79

Abstract:

The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor.

US Patent:

20120028264, Feb 2, 2012

Filed:

Jul 25, 2011

Appl. No.:

13/190391

Inventors:

Steven Shak - Hillsborough CA, US
Frederick L. Baehner - San Francisco CA, US
Tara Maddala - Sunnyvale CA, US
Mark Lee - Los Altos Hills CA, US
Robert J. Pelham - Belmont CA, US
Wayne Cowens - Tiburon CA, US
Diana Cherbavaz - San Francisco CA, US
Michael C. Kiefer - Walnut Creek CA, US
Michael Crager - Menlo Park CA, US
Audrey Goddard - San Francisco CA, US
Joffre B. Baker - Montara CA, US

International Classification:

C12Q 1/68

US Classification:

435 614, 435 61, 435 618, 435 617

Abstract:

Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.

US Patent:

20200263257, Aug 20, 2020

Filed:

Feb 7, 2020

Appl. No.:

16/784696

Inventors:

- Redwood City CA, US
Dominick SINICROPI - Woodside CA, US
Robert J. PELHAM - Belmont CA, US
Michael R. CRAGER - Menlo Park CA, US
Francois COLLIN - Berkeley CA, US
James C. STEPHANS - DECEASED, US
Mei-Lan LIU - San Mateo CA, US
John D. MORLAN - Hayward CA, US
Kunbin QU - Palo Alto CA, US

Assignee:

GENOMIC HEALTH, INC. - Redwood City CA

International Classification:

C12Q 1/6886
G01N 33/574
C12Q 1/686
G16B 20/00

Abstract:

The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient. The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.

US Patent:

20200255911, Aug 13, 2020

Filed:

Feb 25, 2020

Appl. No.:

16/800292

Inventors:

- Redwood City CA, US
Frederick L. BAEHNER - San Francisco CA, US
Tara MADDALA - Sunnyvale CA, US
Mark LEE - Los Altos Hills CA, US
Robert J. PELHAM - Belmont CA, US
Wayne COWENS - , US
Diana CHERBAVAZ - San Francisco CA, US
Michael C. KIEFER - Walnut Creek CA, US
Michael CRAGER - Menlo Park CA, US
Audrey GODDARD - San Francisco CA, US
Joffre B. BAKER - Montara CA, US

Assignee:

GENOMIC HEALTH, INC. - Redwood City CA

International Classification:

C12Q 1/6886

Abstract:

Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.

US Patent:

20190256923, Aug 22, 2019

Filed:

Jan 17, 2019

Appl. No.:

16/250179

Inventors:

- Redwood City CA, US
Dominick SINICROPI - Woodside CA, US
Robert J. PELHAM - Belmont CA, US
Michael R. CRAGER - Menlo Park CA, US
Francois COLLIN - Berkeley CA, US
James C. STEPHANS - Redwood City CA, US
Mei-Lan LIU - San Mateo CA, US
John D. MORLAN - Hayward CA, US
Kunbin QU - Palo Alto CA, US

Assignee:

GENOMIC HEALTH, INC. - Redwood City CA

International Classification:

C12Q 1/6886
G16B 20/00
C12Q 1/686
G01N 33/574

Abstract:

The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient. The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.

US Patent:

20190249260, Aug 15, 2019

Filed:

Feb 22, 2019

Appl. No.:

16/282540

Inventors:

- Redwood City CA, US
Frederick L. BAEHNER - San Francisco CA, US
Tara MADDALA - Sunnyvale CA, US
Mark LEE - Los Altos Hills CA, US
Robert J. PELHAM - Belmont CA, US
Wayne COWENS - , US
Diana CHERBAVAZ - San Francisco CA, US
Michael C. KIEFER - Walnut Creek CA, US
Michael CRAGER - Menlo Park CA, US
Audrey GODDARD - San Francisco CA, US
Joffre B. BAKER - Montara CA, US

Assignee:

GENOMIC HEALTH, INC. - Redwood City CA

International Classification:

C12Q 1/6886

Abstract:

Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.